Review of tocilizumab in the treatment of rheumatoid arthritis

Yasuaki OkudaDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, JapanAbstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology of rheumatoid arthritis (RA). Tocilizumab is...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Yasuaki Okuda
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e217bcd505c740e298f53ae3f08eae46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e217bcd505c740e298f53ae3f08eae46
record_format	dspace
spelling	oai:doaj.org-article:e217bcd505c740e298f53ae3f08eae462021-12-02T03:10:25ZReview of tocilizumab in the treatment of rheumatoid arthritis1177-54751177-5491https://doaj.org/article/e217bcd505c740e298f53ae3f08eae462008-03-01T00:00:00Zhttp://www.dovepress.com/review-of-tocilizumab-in-the-treatment-of-rheumatoid-arthritis-a56https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Yasuaki OkudaDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, JapanAbstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology of rheumatoid arthritis (RA). Tocilizumab is a humanized anti-human IL-6 receptor antibody that binds to soluble and membrane-bound IL-6 receptor, and at detectable levels in blood, tocilizumab is capable of almost completely blocking the transmembrane signaling of IL-6. In clinical trials for patients with RA in Japan, tocilizumab monotherapy has shown clinical efficacy equaling that of tumor necrosis factor (TNF) inhibitor in combination with methotrexate, and in an extension study in patients who responded to tocilizumab, almost no patients showed a decrease in the efficacy of tocilizumab. Evidence obtained in a phase III study in Japan demonstrated that tocilizumab monotherapy had a significant inhibitory effect on the progression of structural joint damage compared with that of conventional disease modifying antirheumatic drugs (DMARDs). Furthermore it has been shown that tocilizumab has an excellent ability to suppress serum amyloid A levels and could therefore be an important therapeutic strategy in amyloid A amyloidosis secondary to rheumatic diseases. The safety profile of tocilizumab appears to be satisfactory. However, several serious infections were also reported, and careful monitoring is therefore important during use.Keywords: tocilizumab, rheumatoid arthritis, interleukin-6, treatment, amyloidosis, biologics Yasuaki OkudaDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 75-82 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Yasuaki Okuda Review of tocilizumab in the treatment of rheumatoid arthritis
description	Yasuaki OkudaDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, JapanAbstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology of rheumatoid arthritis (RA). Tocilizumab is a humanized anti-human IL-6 receptor antibody that binds to soluble and membrane-bound IL-6 receptor, and at detectable levels in blood, tocilizumab is capable of almost completely blocking the transmembrane signaling of IL-6. In clinical trials for patients with RA in Japan, tocilizumab monotherapy has shown clinical efficacy equaling that of tumor necrosis factor (TNF) inhibitor in combination with methotrexate, and in an extension study in patients who responded to tocilizumab, almost no patients showed a decrease in the efficacy of tocilizumab. Evidence obtained in a phase III study in Japan demonstrated that tocilizumab monotherapy had a significant inhibitory effect on the progression of structural joint damage compared with that of conventional disease modifying antirheumatic drugs (DMARDs). Furthermore it has been shown that tocilizumab has an excellent ability to suppress serum amyloid A levels and could therefore be an important therapeutic strategy in amyloid A amyloidosis secondary to rheumatic diseases. The safety profile of tocilizumab appears to be satisfactory. However, several serious infections were also reported, and careful monitoring is therefore important during use.Keywords: tocilizumab, rheumatoid arthritis, interleukin-6, treatment, amyloidosis, biologics
format	article
author	Yasuaki Okuda
author_facet	Yasuaki Okuda
author_sort	Yasuaki Okuda
title	Review of tocilizumab in the treatment of rheumatoid arthritis
title_short	Review of tocilizumab in the treatment of rheumatoid arthritis
title_full	Review of tocilizumab in the treatment of rheumatoid arthritis
title_fullStr	Review of tocilizumab in the treatment of rheumatoid arthritis
title_full_unstemmed	Review of tocilizumab in the treatment of rheumatoid arthritis
title_sort	review of tocilizumab in the treatment of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/e217bcd505c740e298f53ae3f08eae46
work_keys_str_mv	AT yasuakiokuda reviewoftocilizumabinthetreatmentofrheumatoidarthritis
_version_	1718401951054430208

Review of tocilizumab in the treatment of rheumatoid arthritis

Ejemplares similares